Daily Sepsis Research Analysis
Analyzed 53 papers and selected 3 impactful papers.
Summary
Today’s most impactful sepsis research spans three fronts: updated pediatric Surviving Sepsis Campaign guidelines, a nationwide cohort quantifying long-term psychiatric risks after sepsis, and a network meta-analysis refining corticosteroid regimens. Collectively, these works shape immediate pediatric care, inform post-sepsis surveillance, and guide anti-inflammatory therapy choices.
Research Themes
- Guideline-driven standardization of pediatric sepsis care
- Long-term neuropsychiatric outcomes after sepsis
- Optimization of corticosteroid therapy in adult sepsis
Selected Articles
1. Sepsis and Subsequent Psychiatric Morbidity: A Nationwide Population-Based Matched Cohort Study, 2008-2019.
In a Swedish nationwide matched cohort (10,308 ICU-treated sepsis patients vs 155,705 controls), sepsis was linked to markedly increased hazards of incident psychiatric events, strongest within 90 days and persisting up to 5 years. Mediation by new chronic diseases was minimal, suggesting a direct or unmediated sepsis-related effect on long-term psychiatric health.
Impact: This large, methodologically rigorous cohort quantifies long-term psychiatric risks after sepsis, highlighting a critical and under-recognized survivorship issue with implications for screening and preventive care.
Clinical Implications: Post-sepsis care pathways should include routine mental health screening (especially in the first year), early referral mechanisms, and patient/caregiver education. Health systems should integrate survivorship clinics with psychiatric support.
Key Findings
- Sepsis was associated with sharply increased psychiatric event hazards within 0–90 days (aHR 6.2 to 7.4), attenuating but persisting up to 5 years.
- Landmark analyses showed elevated risk at 91–365 days (aHR 2.3) and sustained elevation at 1–3 and 3–5 years.
- Mediation by incident chronic diseases was minimal, indicating limited confounding via new comorbidities.
Methodological Strengths
- Nationwide, population-based matched cohort with linkage across multiple high-quality Swedish registries
- Weighted Cox regression with landmark analyses to address time-varying hazards and confounding
Limitations
- Observational design with potential residual confounding despite matching and weighting
- Outcome definition relied on prescriptions and specialist-care diagnoses, potentially missing subclinical morbidity
Future Directions: Prospective interventional studies testing early mental health screening and preventive strategies post-sepsis; mechanistic studies on neuroinflammation and brain injury in sepsis survivors.
OBJECTIVES: To quantify the risk of incident psychiatric morbidity after community-acquired sepsis and assess whether new chronic diseases mediate the association. DESIGN: Nationwide, population-based matched register cohort; hazards estimated with weighted Cox regression. SETTING: Sweden, linking the National Quality Sepsis Registry, National Patient Register, Prescribed Drug Register, and population registers. PATIENTS: Ten thousand three hundred eight adults (≥ 18 yr) treated in an ICU for sepsis (2008-2019), matched to 155,705 population controls by sex, age, region, and year. Individuals with a psychiatric diagnosis within 5 years or psychotropic medication within 1 year before index were excluded. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The primary outcome, psychiatric event, was first occurrence after index date of either initiation of a psychotropic medication (anatomic therapeutic chemical classification system code N05A, N05BA, N05C, N06A) in the Prescribed Drug Register (capturing prescriptions from primary and specialist care) or a new International Classification of Diseases, 10th Edition mood (F3) or anxiety (F4) diagnosis in specialist care. Weighted Cox models balanced baseline covariates. We used a Landmark approach with risk sets at 0-30, 31-90, 91-365 days; 1-3, 3-5, and greater than or equal to 5 years after the index date. Sepsis was associated with increased hazards of psychiatric events vs. matched controls, with the strongest associations in the first year (0-30 d: adjusted hazard ratio [aHR], 6.2 [5.0-7.7]; 31-90 d: aHR, 7.4 [6.5-8.6]; and 91-365 d: aHR, 2.3 [2.1-2.5]) attenuating over time but remaining elevated through 5 years (1-3 yr: aHR, 1.2 [1.1-1.5]; 3-5 yr: aHR, 1.3 [1.1-1.5]; and ≥ 5 yr: aHR, 1.1 [0.9-1.3]). In mediation analyses considering incident chronic diseases, estimates changed little, suggesting that these conditions did not mediate the association. CONCLUSIONS: Patients with sepsis had a higher subsequent incidence of psychiatric events compared with matched population controls, with a persistently elevated risk for at least 5 years. This increased risk suggests that sepsis may have a long-term impact on psychiatric health, warranting consideration of preventive strategies.
2. Corticosteroids for Treating Sepsis: A Systematic Review and Network Meta-analysis.
Across 18 RCTs (7,591 patients), corticosteroids reduced short- and long-term mortality and improved organ support metrics, with regimen-specific signals (e.g., hydrocortisone 200 mg/day and hydrocortisone plus fludrocortisone). However, the apparent mortality benefit of hydrocortisone 100 mg/day rests on a single small RCT and requires confirmation.
Impact: By comparing doses and regimens with network methods, this analysis informs practical corticosteroid choices in sepsis beyond binary use/no-use debates.
Clinical Implications: Consider hydrocortisone-based regimens for septic shock while recognizing regimen-specific benefits and the preliminary nature of some findings; tailor dosing to patient context until higher-certainty data define an optimal regimen.
Key Findings
- Corticosteroids reduced ≤30-day and ≥90-day mortality across included RCTs.
- Hydrocortisone 200 mg/day shortened ICU length of stay and improved organ support-free days; adding fludrocortisone increased ventilator/vasopressor-free days.
- Hydrocortisone 100 mg/day mortality benefit is based on one small RCT and should be interpreted cautiously.
Methodological Strengths
- Network meta-analysis of RCTs with PROSPERO registration and multi-database search
- Regimen-level comparisons with SUCRA ranking and assessment of multiple clinically relevant outcomes
Limitations
- Heterogeneity across trials and potential inconsistency in the network
- Some nodes (e.g., H 100 mg/day) supported by limited/small trials; potential publication bias
Future Directions: Head-to-head RCTs to confirm optimal dosing and the role of mineralocorticoid co-administration; subgroup analyses for precision dosing (e.g., shock phenotype, renal function).
PURPOSE: Corticosteroids have been applied in sepsis treatment for decades, yet their clinical efficacy-particularly regarding optimal dosage, administration regimens, and impact on long-term prognosis-remains controversial and incompletely defined. This systematic review and network meta-analysis aimed to comprehensively evaluate corticosteroids' effect on improving sepsis patients' outcomes and clarify the comparative effectiveness of different corticosteroid dosages and regimens. MATERIALS AND METHODS: Four electronic databases (PubMed, Embase, Web of Science, Cochrane Library) were searched from inception to March 2023 to identify randomized controlled trials (RCTs) of corticosteroids in adult sepsis patients. R software, Stata 15.0, and RevMan 5.4 analyzed data. Primary outcomes (≤30-day short-term mortality, ≥90-day long-term mortality) and secondary outcomes (ICU length of stay [LOS], mechanical ventilator-free days, vasopressor-free days, renal replacement therapy-free days) were synthesized. Surface under the cumulative ranking curve (SUCRA) ranked efficacy; funnel plots assessed publication bias. The study was prospectively registered on PROSPERO (CRD 42023454288). RESULTS: A total of 18 eligible RCTs involving 7,591 patients were included. Corticosteroids reduced ≤30-day mortality (hydrocortisone [H] 100 mg/d: odds ratio [RR]=0.22, 95% CI=0.072-0.62), this finding is based on one small-scale RCT and requires confirmatory studies) and ≥90-day mortality (H 100 mg/d: RR=0.33; H 200 mg/d+fludrocortisone 50 μg/d: RR=0.79). Specific regimens improved secondary outcomes: H 200 mg/d shortened ICU LOS (mean difference [MD]=-2.6), H 200 mg/d+fludrocortisone increased ventilator/vasopressor-free days, and H 300 mg/d prolonged renal replacement therapy-free days. CONCLUSION: Notably, the mortality benefit of H 100 mg/d is preliminary due to limited evidence from a single small RCT. Corticosteroids reduce sepsis patients' short/long-term mortality and organ support duration, but no "optimal" dosage consensus exists. Further research is needed to refine dosage and personalize therapy.
3. Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026.
The 2026 pediatric Surviving Sepsis Campaign provides 61 statements (5 strong, 24 conditional, 10 good practice), with many new or revised recommendations since 2020, yet acknowledges low certainty for most areas. It offers structured, GRADE-based guidance across pediatric ages while identifying evidence gaps.
Impact: These consensus guidelines immediately shape pediatric sepsis care globally and delineate research priorities where evidence remains weak.
Clinical Implications: Clinicians should align pediatric sepsis management with GRADE-based statements while recognizing low-certainty areas; institutions should update pathways and monitor outcomes as new evidence emerges.
Key Findings
- A total of 61 statements were issued: 5 strong recommendations, 24 conditional, and 10 good practice statements.
- Compared with 2020, 20 recommendations are new and 13 updated; only three recommendations are based on high or moderate certainty.
- An evidence-to-decision framework and GRADE were systematically applied by a 68-member international panel.
Methodological Strengths
- Comprehensive systematic reviews with GRADE and explicit evidence-to-decision framework
- International multidisciplinary panel with formal conflict-of-interest management
Limitations
- Most recommendations rest on low or very low certainty evidence
- Some priority PICO questions lacked sufficient evidence to support recommendations
Future Directions: Conduct pediatric-specific RCTs targeting high-priority PICO questions (e.g., resuscitation strategies, vasoactive choices, timing of interventions) to upgrade certainty.
OBJECTIVES: To update evidence-based management recommendations for clinicians caring for children (including infants, school-aged children, and adolescents) with sepsis or septic shock. DESIGN: A panel of 68 international experts, representing 13 international organizations, as well as six methodologists, was convened. A formal conflict-of-interest policy was developed at the onset of the process and applied throughout. Teleconferences and electronic-based discussion among the chairs, co-chairs, methodologists, and subgroup leads as well as within subgroups, served as an integral part of the guideline development process. METHODS: New priority topics and recommendations from the prior guideline iteration were used to identify Population, Intervention, Control, and Outcomes (PICO) questions likely to have new or updated evidence. We conducted a systematic review to identify the best available evidence, summarized the evidence, and then assessed the quality of evidence using the Grading of Recommendations, Assessment, Development, and Evaluation approach. We used the evidence-to-decision framework to formulate recommendations as strong or conditional, or as a good practice statement. "In our practice," statements were included when evidence was inconclusive to issue a recommendation but the panel felt that some guidance based on practice patterns may be appropriate. RESULTS: The panel provided 61 statements on the management of children with sepsis or septic shock. Overall, five were strong recommendations, 24 were conditional recommendations, and ten were good practice statements. For 22 PICO questions, no recommendations could be made, but, for seven of these, "in our practice" statements were provided. Compared with the 2020 guidelines, 20 recommendations were new, 13 were updated for clarity and/or new evidence, six were reviewed but not changed, and 22 were carried forward based on consensus of the panel that new evidence was not available. Only three recommendations were based on high or moderate certainty of evidence. CONCLUSIONS: Updated management guidelines were issued by a panel of international experts for the best care of children with sepsis or septic shock, acknowledging that most aspects of care continue to have relatively low quality of evidence.